First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Paz-Ares Luis; Ciuleanu Tudor-Eliade; Cobo Manuel; Schenker Michael; Zurawski Bogdan; Menezes Juliana; Richardet Eduardo; Bennouna Jaafar; Felip Enriqueta; Juan-Vidal Oscar; Alexandru Aurelia; Sakai Hiroshi; Lingua Alejo; Salman Pamela; Souquet Pierre-Jean; De Marchi Pedro; Martin Claudio; Perol Maurice; Scherpereel Arnaud; Lu Shue; John Thomas; Carbone David P.; Meadows-Shropshire Stephanie; Agrawal Shruti; Oukessou Abderrahim; Yan Jinchun; Reck Martin

首页> 外文期刊>The lancet oncology >First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

【24h】

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

机译：第一线Nivolumab加IPILIMIMAB与非小细胞肺癌患者的两次化疗（Checkmate 9LA）：国际，随机，开放标签，第3阶段试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background First-line nivolumab plus ipilimumab has shown improved overall survival in patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate whether the addition of a limited course (two cycles) of chemotherapy to this combination would further enhance the clinical benefit.

机译：背景：一线nivolumab加ipilimumab已显示改善晚期非小细胞肺癌（NSCLC）患者的总体生存率。我们的目的是研究在这种联合疗法中增加有限疗程（两个周期）的化疗是否会进一步提高临床效益。

著录项

来源
《The lancet oncology》 |2021年第2期|共14页
作者
Paz-Ares Luis; Ciuleanu Tudor-Eliade; Cobo Manuel; Schenker Michael; Zurawski Bogdan; Menezes Juliana; Richardet Eduardo; Bennouna Jaafar; Felip Enriqueta; Juan-Vidal Oscar; Alexandru Aurelia; Sakai Hiroshi; Lingua Alejo; Salman Pamela; Souquet Pierre-Jean; De Marchi Pedro; Martin Claudio; Perol Maurice; Scherpereel Arnaud; Lu Shue; John Thomas; Carbone David P.; Meadows-Shropshire Stephanie; Agrawal Shruti; Oukessou Abderrahim; Yan Jinchun; Reck Martin;
展开▼
作者单位

Univ Complutense Hosp Univ 12 Octubre CNIO H12o Lung Canc Unit Madrid 28041 Spain;

Inst Oncol Prof Dr Ion Chiricuta &

UMF Iuliu Hati Cluj Napoca Romania;

Hospit Univ Reg &

Virgen Victoria IBIMA Unidad Gest Clin Intercentros Oncol Med Malaga Spain;

SF Nectarie Oncol Ctr Craiova Romania;

Ambulatorium Chemioterapii Bydgoszcz Poland;

Hosp Nossa Senhora Conceicao Porto Alegre RS Brazil;

Inst Oncol Cordoba Cordoba Argentina;

Univ Hosp Nantes Thorac Oncol Unit Nantes France;

Vall dHebron Univ Hosp Vall dHebron Inst Oncol Barcelona Spain;

Hosp Univ La Fe Valencia Spain;

Inst Oncol Prof Dr AlexandruTrestioreanu Bucha Bucharest Romania;

Saitama Canc Ctr Saitama Japan;

Inst Med Rio Cuarto SA Cordoba Argentina;

Fdn Arturo Lopez Perez Santiago Metropolitana Chile;

Hop Lyon Sud Lyon Pierre Benite France;

Barretos Canc Hosp Barretos Brazil;

Inst Alexander Fleming Buenos Aires DF Argentina;

Leon Berard Canc Ctr Lyon France;

Univ Lille CHU Lille INSERM U1189 OncoThAI Pulm &

Thorac Oncol Lille France;

Shanghai Jiao Tong Univ Shanghai Chest Hosp Shanghai Lung Canc Ctr Shanghai Peoples R China;

Austin Hosp Heidelberg Vic Australia;

Ohio State Univ Ctr Comprehens Canc Columbus OH 43210 USA;

Bristol Myers Squibb Princeton NJ USA;

Bristol Myers Squibb Princeton NJ USA;

Bristol Myers Squibb Princeton NJ USA;

Bristol Myers Squibb Princeton NJ USA;

German Ctr Lung Res LungClin Airway Res Ctr North Dept Thorac Oncol Grosshansdorf Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A Phase II Clinical Trial of Celecoxib Combined with Platinum-Based Regimen as First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer Patients with Cyclooxygenase-2 Positive Expression [J] . Jun Zhao, Mei-na Wu, Xu-yi Liu, 中国癌症研究（英文版） . 2009,第001期
2. Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: A phase Ⅱ open-label clinical study [J] . Shanshan Qin, Jie Qiao, Yu Feng, 中国癌症研究（英文版） . 2019,第002期
3. Nab-paclitaxel (abraxane)-based chemotherapy to treat elderly patients with advanced non-small-cell lung cancer: a single center, randomized and open-label clinical trial [J] . Hanrui Chen, Xuewu Huang, Shutang Wang, 中国癌症研究（英文版） . 2015,第002期
4. A Phase II Trial of Gefitinib as Maintenance Therapy after First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer in China [J] . Lu Yang, Zhi-jie Wang, Tong-tong An, 中国癌症研究：英文版 . 2010,第001期
5. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-smallcell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial (vol 22, pg 198, 2021) [J] . Paz-Ares L., Ciuleanu T-E, Cobo M. The lancet oncology . 2021,第3期

机译：第一线Nivolumab加IPILIMIMAB与非小型肺癌患者的两个化疗（Checkmate 9LA）相结合：国际，随机，开放标签，第3阶段试验（Vol 22，PG 198,2021）
6. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial [J] . Reck Martin, Schenker Michael, Lee Ki Hyeong, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：Nivolumab Plus inpilemimab与化疗作为高级非小细胞肺癌的一线治疗，具有高肿瘤突变负担：患者报告的结果由随机，开放标签，III期检查培育227试验结果
7. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study [J] . Hellmann Matthew D., Rizvi Naiyer A., Goldman Jonathan W., The lancet oncology . 2017,第1期

机译：Nivolumab Plus IpiLimumab作为高级非小细胞肺癌的一线治疗（Checkmate 012）：开放标签，阶段1，多级研究的结果
8. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
9. Subgroup analysis based on prognostic and predictive gene signatures for adjuvant chemotherapy in early-stage non-small-cell lung cancer patients [D] . Pluta, Dustin. 2015

机译：基于预后和预测基因特征的亚组分析用于早期非小细胞肺癌患者的辅助化疗
10. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label phase 1 multicohort study [O] . Matthew D Hellmann, Prof. Naiyer A Rizvi, Jonathan W Goldman, -1

机译：Nivolumab + ipilimumab作为晚期非小细胞肺癌的一线治疗药物（CheckMate 012）：开放标签1期多队列研究的结果
11. LBA59 First-line nivolumab (NIVO) + ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA [O] . M. Reck, T-E. Ciuleanu, M. Cobo, 2020

机译：LBA59第一线Nivolumab（Nivo）+ Ipilimumab（IPI）与2个铂类化疗（Chemo）的循环相结合，在先进的非小细胞肺癌（NSCLC）中的化疗中的4个循环：患者报告的结果（专业） checkmate 9la.
12. Phase 1 Trial of an Immune Checkpoint Inhibitor plus Stereotactic Ablative Radiotherapy in Patients with Inoperable Stage I Non-Small Cell Lung Cancer. [R] . Kelly, K., Monjazeb, A., Daly, M., 2017

机译：免疫检查点抑制剂加立体定向消融放疗治疗不能手术的I期非小细胞肺癌的1期试验。

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

摘要

著录项

相似文献

相关主题

期刊订阅